Conference abstractPublished 17 Sep 2018
Synthetic oligosaccharides can replace animal-sourced low-molecular weight heparins
University of North Carolina at Chapel Hill, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Low-molecular weight heparin (LMWH) is used clinically to treat clotting disorders. As an animal-sourced product, LMWH’s supply chain reliability is a concern for regulatory agencies. Here, we demonstrate the synthesis of heparin dodecasaccharides (12-mers) at gram-scale. In vitro and ex vivo experiments demonstrate that the anticoagulant activity of the 12-mers could be reversed using protamine. The 12-mer-1 reduced the size of blood clot in the mouse model of deep vein thrombosis, and attenuated circulating procoagulant markers in the mouse model of sickle-cell disease. The 12-mer- 1 was examined in a non-human primate model to determine its pharmacodynamic parameters. A 7-day toxicity study in a rat model showed no toxic effects. The data suggest that a synthetic homogeneous oligosaccharide can replace animalsourced LMWHs. In this seminar, the synthesis of homogenous LMWH, in vitro and ex vivo studies which demonstrate that the anticoagulant activity and reversibility of synthetic dodecasaccharides, and animal studies which suggest a synthetic homogeneous oligosaccharide can replace animal-sourced LMWHs will be discussed.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Glycobiology
- SubjectGenetics & Molecular Biology
- SubjectObesity & Weight Management
- SubjectVeterinary & Animal Science
- BylineArticles whose byline prints “Yongmei Xu”
